Voyager Therapeutics, Inc. files with the SEC under CIK 0001640266 and is classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 9, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.47, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.47, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.47, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.72 to $3.90, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.68 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.71 to $3.91, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 33,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 86,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Consists of shares of common stock issuable under an aggregate of 32,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter adopted by the reporting person on May 9, 2025 effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.85, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange… Full note on SEC EDGAR
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
Voyager Therapeutics, Inc. (VYGR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-11. The full record for VYGR runs to 34 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying VYGR stock?
No insider purchases of VYGR were filed in the last 90 days.
How many insiders are selling VYGR stock?
No insider sales of VYGR were filed in the last 90 days. 15 sales are on record for this company.
Where can I see VYGR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects VYGR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Michael J. Higgins - Director
Jude Onyia - Director
Nathan D. Jorgensen - Officer
